Expression and prognosis analysis of family in acute myeloid leukemia.

DNA methyltransferases () by regulating DNA methylation play crucial roles in the progression of hematologic malignancies, especially for acute myeloid leukemia (AML). Accumulating investigations have identified the high incidence of mutation in AML, and it is correlated with poor prognosis. Although a few studies have shown the expression of and their clinical significance in AML, the results remain to be discussed. Herein, we systemically analyzed the expression and their relationship with clinic-pathological features and prognosis in AML patients. expression especially for / was closely associated with AML among various human cancers. expression was increased in AML patients, whereas expression was decreased. Significant associations between / expression and clinic-pathological features/gene mutations were observed. Kaplan-Meier analysis showed that expression was associated with better overall survival (OS) and leukemia-free survival (LFS) among whole-cohort AML, and independently affected OS determined by Cox repression multivariate analysis. Notably, patients that received hematopoietic stem cell transplantation (HSCT) showed significantly better OS and LFS in lower-expressed groups, whereas patients in higher-expressed groups did not. By bioinformatics analysis, expression was found to be positively correlated with several leukemia-associated genes/microRNAs, and was identified as direct targets of and in AML. Collectively, our study demonstrated that / showed significant expression differences in AML. expression acted as a potential prognostic biomarker and may guide treatment choice between chemotherapy and HSCT in AML.